TaiTsun (4169) Corrects Misstatements in Q1 2026 Consolidated Financial Report
TaiTsun Biopharmaceutical Co., Ltd. announced a correction to its Q1 2026 (Minguo 115) consolidated financial report. The errors in the cash flow statement involved incorrect signs for 'Interest expense' and 'Interest paid,' and the omission of 'Interest income' and 'Interest received.' The company will correct the relevant consolidated report and iXBRL filing.
📋 Article Processing Timeline
- 📰 Published: May 21, 2026 at 06:31
- 🔍 Collected: May 21, 2026 at 06:31 (0 min after Published)
- 🤖 AI Analyzed: May 21, 2026 at 07:03 (31 min after Collected)
Date of issue: 2026/05/21
Date of statement: 2026/05/20
Time of statement: 17:11:47
Company code: 4169
Company name: TaiTsun
Subject: Correction of misstatements in the Company's Q1 2026 consolidated financial report
Applicable clause: Article 51
Date of occurrence: 2026/05/20
Description:
1. Date of occurrence: 2026/05/20
2. Company name: TaiTsun Biopharmaceutical Co., Ltd.
3. Relationship to the Company: The Company
4. Mutual shareholding ratio: Not applicable
5. Reason for occurrence: In the Q1 2026 cash flow statement, the signs for 'Interest expense' and 'Interest paid' were incorrect, and 'Interest income' and 'Interest received' were omitted.
6. Corrected information item/report name: The Company's Q1 2026 consolidated financial report, Q1 2026 iXBRL filing information
7. Amount/content/page before correction:
Cash Flow Statement Page 10
From Jan 1, 2026 to Mar 31, 2026 / From Jan 1, 2025 to Mar 31, 2025
----------------------------------------------------
Interest expense (166) / (226)
Interest paid 166 / 226
8. Amount/content/page after correction:
Cash Flow Statement Page 10
From Jan 1, 2026 to Mar 31, 2026 / From Jan 1, 2025 to Mar 31, 2025
----------------------------------------------------
Interest expense 166 / 226
Interest...
Date of statement: 2026/05/20
Time of statement: 17:11:47
Company code: 4169
Company name: TaiTsun
Subject: Correction of misstatements in the Company's Q1 2026 consolidated financial report
Applicable clause: Article 51
Date of occurrence: 2026/05/20
Description:
1. Date of occurrence: 2026/05/20
2. Company name: TaiTsun Biopharmaceutical Co., Ltd.
3. Relationship to the Company: The Company
4. Mutual shareholding ratio: Not applicable
5. Reason for occurrence: In the Q1 2026 cash flow statement, the signs for 'Interest expense' and 'Interest paid' were incorrect, and 'Interest income' and 'Interest received' were omitted.
6. Corrected information item/report name: The Company's Q1 2026 consolidated financial report, Q1 2026 iXBRL filing information
7. Amount/content/page before correction:
Cash Flow Statement Page 10
From Jan 1, 2026 to Mar 31, 2026 / From Jan 1, 2025 to Mar 31, 2025
----------------------------------------------------
Interest expense (166) / (226)
Interest paid 166 / 226
8. Amount/content/page after correction:
Cash Flow Statement Page 10
From Jan 1, 2026 to Mar 31, 2026 / From Jan 1, 2025 to Mar 31, 2025
----------------------------------------------------
Interest expense 166 / 226
Interest...